M4K Pharma is using open science to revolutionize how affordable new treatments are discovered and developed. Through their Medicines4Kids program, we are aggregating and aligning the work of global academics, foundations and pharma/biotech researchers to advance new cures for childhood diseases not well served by current business models.

M4K Pharma’s first program is the discovery, development and commercialization of an ALK2 enzyme inhibitor which will provide the first therapeutic developed specifically for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).

VISION 
A world where every child has access to life-saving treatments.

MISSION
To use open science to revolutionize how affordable new treatments are discovered and developed. By aggregating and aligning the work of global academics, foundations and pharma/biotech researchers, they will advance new cures for childhood diseases not well served by current business models.